Skip to main content
Top
Published in: Infection 6/2022

Open Access 16-06-2022 | Schizophrenia | Correspondence

No link between the prevalence of hepatitis E virus infection and the diagnosis of schizophrenia

Authors: Claudia Beisel, Sven Pischke, Maria Mader, Steffen Moritz, Daniel Schöttle, Daniel Lüdecke

Published in: Infection | Issue 6/2022

Login to get access

Excerpt

Infection with the Hepatitis E Virus (HEV) may cause strong inflammation of the liver and represents one of the most common causes of acute hepatitis in the world. Extrahepatic manifestations, such as neurological, hematological, or renal manifestation as well as several autoimmune phenomena have been reported in association with HEV infection [1]. There are only limited data about the association between HEV infection and psychiatric disorders. Few epidemiological studies from Taiwan, China, and Germany, demonstrated high anti-HEV IgG seroprevalence rates in psychiatric patients [25]. However, these studies often lack adequate control cohorts, making it difficult to adequately classify seroprevalence rates. Systematic studies that address the risk of psychiatric patients acquiring HEV infection, or if a previous HEV infection may trigger psychiatric diseases are missing. …
Literature
1.
go back to reference Pischke S, Hartl J, Pas SD, Lohse AW, Jacobs BC, van der Eijk AA. Hepatitis E virus: Infection beyond the liver? J Hepatol. 2017;66:1082–95.CrossRefPubMed Pischke S, Hartl J, Pas SD, Lohse AW, Jacobs BC, van der Eijk AA. Hepatitis E virus: Infection beyond the liver? J Hepatol. 2017;66:1082–95.CrossRefPubMed
2.
go back to reference Cong W, Meng Q-F, Li B, Ma F-L, Qian A-D, Wang X-Y, Yu C-Z, Zhu X-Q. Seroprevalence of hepatitis E virus infection in psychiatric patients and control subjects in Shandong Province, eastern China. Int J Infect Dis. 2014;28:70–3.CrossRefPubMed Cong W, Meng Q-F, Li B, Ma F-L, Qian A-D, Wang X-Y, Yu C-Z, Zhu X-Q. Seroprevalence of hepatitis E virus infection in psychiatric patients and control subjects in Shandong Province, eastern China. Int J Infect Dis. 2014;28:70–3.CrossRefPubMed
3.
go back to reference Reinheimer C, Allwinn R, Berger A. Hepatitis E: are psychiatric patients on special risk? Med Microbiol Immunol. 2012;201:171–5.CrossRefPubMed Reinheimer C, Allwinn R, Berger A. Hepatitis E: are psychiatric patients on special risk? Med Microbiol Immunol. 2012;201:171–5.CrossRefPubMed
4.
go back to reference Cheng P-N, Wang R-H, Wu I-C, Wu J-C, Tseng K-C, Young K-C, Chang T-T. Seroprevalence of hepatitis E virus infection among institutionalized psychiatric patients in Taiwan. J Clin Virol. 2007;38:44–8.CrossRefPubMed Cheng P-N, Wang R-H, Wu I-C, Wu J-C, Tseng K-C, Young K-C, Chang T-T. Seroprevalence of hepatitis E virus infection among institutionalized psychiatric patients in Taiwan. J Clin Virol. 2007;38:44–8.CrossRefPubMed
5.
go back to reference Xue Y, Sun X, Li Y, Liu X, Dong C. Increased risk of hepatitis E virus infection in schizophrenia. Adv Virol. 2013;158:359–65. Xue Y, Sun X, Li Y, Liu X, Dong C. Increased risk of hepatitis E virus infection in schizophrenia. Adv Virol. 2013;158:359–65.
6.
go back to reference Faber M, Willrich N, Schemmerer M, Rauh C, Kuhnert R, Stark K, Wenzel JJ. Hepatitis E virus seroprevalence, seroincidence and seroreversion in the German adult population. J Viral Hepatitis. 2018;25:752–8.CrossRef Faber M, Willrich N, Schemmerer M, Rauh C, Kuhnert R, Stark K, Wenzel JJ. Hepatitis E virus seroprevalence, seroincidence and seroreversion in the German adult population. J Viral Hepatitis. 2018;25:752–8.CrossRef
Metadata
Title
No link between the prevalence of hepatitis E virus infection and the diagnosis of schizophrenia
Authors
Claudia Beisel
Sven Pischke
Maria Mader
Steffen Moritz
Daniel Schöttle
Daniel Lüdecke
Publication date
16-06-2022
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 6/2022
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-022-01871-2

Other articles of this Issue 6/2022

Infection 6/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine